1736-20-5

Basic information

• Product Name: 3-(2-FLUORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID
• Synonyms: ASINEX-REAG BAS 10140988;3-(2-FLUORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID;BAS 10140988;ST5289332
• CAS NO: 1736-20-5
• Molecular Formula: C₁₁H₈FNO₃
• Molecular Weight: 221.18
• Mol File: 1736-20-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(2-FLUORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-FLUORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID(1736-20-5)
• EPA Substance Registry System: 3-(2-FLUORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID(1736-20-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 1736-20-5(Hazardous Substances Data)

Upstream product

• 1960-93-6 methyl-3-(2-fluorophenyl)-5-methylisoxazol-4-carboxylate 
• 39502-43-7 2-fluoro-N-hydroxybenzenecarboxymidoyl chloride 
• 34284-28-1 sodium methyl acetoacetate 
• 394-47-8 2-fluorobenzonitrile 
• 1159600-04-0 ethyl 3-(2-fluorophenyl)-5-methylisoxazole-4-carboxylate 

Downstream Products

• 334971-32-3 N-(3,4,5-trimethoxyphenyl) 3-(5-methyl-3-(2-fluoro-phenyl)isoxazol-4-oyl)aminophenyl acetamide 
• 10100-04-6 6β-[3-(2-fluoro-phenyl)-5-methyl-isoxazole-4-carbonylamino]-penicillanic acid 

Relevant articles and documents

Design, synthesis and in vitro biological evaluation of isoxazol-4-carboxa piperidyl derivatives as new anti-influenza A agents targeting virus nucleoprotein

Influenza infection is a major cause of morbidity and mortality during seasonal epidemics and sporadic pandemics. It is important and urgent to develop new anti-influenza agents with a new mechanism of action. Nucleozin has been reported as a potent antagonist of nucleoprotein accumulation in the nucleus. In this study, a new series of isoxazol-4-carboxa piperidyl derivatives 1a-j were synthesized and their chemical structures were confirmed by 1H, 13C NMR and mass spectral data. Furthermore, all the synthesized compounds were evaluated for in vitro anti-influenza virus activity against influenza virus (A/PR/8/34 H1N1). Among all the compounds, 1a, 1b, 1c, 1f and 1g exhibited more potent activity than the standard drug, and compound 1b has showed most promising anti-influenza virus activity. These results are also consistent with the docking study results in terms of the design of compounds targeting influenza A via viral nucleoprotein.

Compounds and method for inhibiting MRP1

The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.